AB3A Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Durable PMO FranchiseThe PMO franchise provides an established commercial base within DMD, supported by high adherence and a substantial treated-patient population. Its 75% quarterly and 78% first-half gross margins indicate that this recurring product business can contribute meaningful, scalable economics.
Improved Operating DisciplineLower operating expenses and positive operating income show that Sarepta has improved cost discipline while continuing to fund its commercial and development activities. If maintained, this operating model can strengthen earnings quality and reduce the resources required to support future growth.
Reduced Gene-therapy Legal OverhangResolving the AAVrh74 patent litigation removes a material legal uncertainty around ELEVIDYS and the company’s gene-therapy platform. The release from specified past and future claims should improve strategic flexibility and allow management to focus more directly on commercial execution and development.
Bears Say
ELEVIDYS Revenue PressureELEVIDYS is an important growth driver, yet recent demand and backlog conversion trends point to weaker near-term product revenue. The approximately six-month enrollment-to-infusion lag means improved enrollment may not support results until 2027, leaving the business exposed to prolonged top-line pressure.
Persistent Cash BurnSustained negative operating and free cash flow means Sarepta has not demonstrated durable self-funding operations. Continued cash burn can constrain investment choices and increase reliance on collaboration receipts, financing, or successful product execution to fund its pipeline and obligations.
Regulatory And Competitive ConstraintsClinical holds limit progress in the LGMD program until safety data support a regulatory pathway, while potential exon-skipping competitors could pressure the established PMO franchise. Together, these constraints may narrow pipeline optionality and challenge long-term growth across Sarepta’s rare-disease portfolio.
Sarepta Therapeutics News
AB3A FAQ
What was Sarepta Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Sarepta Therapeutics’s market cap?
Sarepta Therapeutics’s market cap is CHF1.64B.
When is Sarepta Therapeutics’s upcoming earnings report date?
Sarepta Therapeutics’s upcoming earnings report date is Nov 04, 2026 which is in 37 days.
How were Sarepta Therapeutics’s earnings last quarter?
Sarepta Therapeutics released its earnings results on Aug 05, 2026. The company reported -CHF0.041 earnings per share for the quarter, missing the consensus estimate of CHF0.178 by -CHF0.219.
Is Sarepta Therapeutics overvalued?
According to Wall Street analysts Sarepta Therapeutics’s price is currently Undervalued.
Does Sarepta Therapeutics pay dividends?
Sarepta Therapeutics does not currently pay dividends.
What is Sarepta Therapeutics’s EPS estimate?
Sarepta Therapeutics’s EPS estimate is 0.14.
How many shares outstanding does Sarepta Therapeutics have?
Sarepta Therapeutics has 105,627,020 shares outstanding.
What happened to Sarepta Therapeutics’s price movement after its last earnings report?
Sarepta Therapeutics reported an EPS of -CHF0.041 in its last earnings report, missing expectations of CHF0.178. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Sarepta Therapeutics?
Currently, no hedge funds are holding shares in CH:AB3A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sarepta Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
CHF18.48 (― Upside)
CHF18.48 (― Upside)
Blogger Sentiment
Bullish
CH:AB3A Sentiment 73%
Sector Average 64%
Sector Average 64%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.36%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.35%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Sarepta Therapeutics
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
AB3A Company Deck
AB3A Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: Sarepta demonstrated strong operational discipline (GAAP and non-GAAP profitability), meaningful cash growth, expense reductions, and progress across its siRNA and regulatory programs — all positive signs. However, a substantial year-over-year revenue decline (34% in Q2) driven by lower ELEVIDYS demand, near-term expectations for modestly lower product revenue in H2, a $39M litigation charge, and timing delays for key safety readouts temper the outlook. Pipeline catalysts and accepted sNDAs provide upside potential, but near-term top-line pressure and regulatory/timing uncertainties leave the narrative mixed.View all CH:AB3A earnings summariesAB3A Stock 12 Month Forecast
Average Price Target
―Ultragenyx Pharmaceutical
―
uniQure
―
Wave Life Sciences
―
Solid Biosciences
―
Taysha Gene Therapies
―